MARKET

RAPP

RAPP

Rapport Therapeutics Inc
NASDAQ
27.84
-1.16
-4.00%
After Hours: 28.45 +0.61 +2.19% 18:42 03/27 EDT
OPEN
28.60
PREV CLOSE
29.00
HIGH
28.95
LOW
27.23
VOLUME
291.60K
TURNOVER
--
52 WEEK HIGH
42.27
52 WEEK LOW
7.73
MARKET CAP
1.33B
P/E (TTM)
-9.7230
1D
5D
1M
3M
1Y
5Y
1D
Rapport Therapeutics; Chief Development Officer Yeleswaram Krishnaswamy sells 10,115 common shares for $303,000
Reuters · 3d ago
Weekly Report: what happened at RAPP last week (0316-0320)?
Weekly Report · 6d ago
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP)
TipRanks · 03/18 05:40
Weekly Report: what happened at RAPP last week (0309-0313)?
Weekly Report · 03/16 09:50
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC)
TipRanks · 03/12 08:20
Rapport Therapeutics Is Maintained at Buy by BTIG
Dow Jones · 03/11 18:32
Rapport Therapeutics Price Target Raised to $53.00/Share From $47.00 by BTIG
Dow Jones · 03/11 18:32
BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $53
Benzinga · 03/11 18:22
More
About RAPP
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.

Webull offers Rapport Therapeutics Inc stock information, including NASDAQ: RAPP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RAPP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RAPP stock methods without spending real money on the virtual paper trading platform.